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cillinMICs≤2 and≤0.06g/ml indicates amoxicillin and ampicillin
susceptibility, respectively. Serotype 19A made up 72% of drug
resistant clinical isolates and almost half of 19A clinical isolates
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ealthy adults, children and infants
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Background: Rotavirus is the leading cause of acute gastroen-
eritis in infants worldwide. RotaTeqTM is approved for preventing
otavirus gastroenteritis in infants in many countries; this is the
rst study of RotaTeqTM in China.
Methods: Randomized (1:1), placebo-controlled, double-blind,
ingle site study in Chinese adults (19-47 years, Cohort I), children
2-6 years, Cohort II), and infants (6-12 weeks for ﬁrst dose, Cohort
II). Cohorts I and II received 1 dose (RotaTeqTM or placebo); Cohort
II received 3 doses at 4-10week intervalswith the 3rd dose admin-
stered by 32 weeks of age. The objective was to assess vaccine
afety. Participants were followed for adverse events (AEs) includ-
ng elevated temperature, vomiting, and diarrhea through 14 days
fter any dose. Serious adverse events (SAEs), deaths, and intus-
usception were collected throughout the study. In Cohort III, two
tool sampleswere collected 3-7 days following each dose to assess
accine-virus shedding.
Results: A total of 144 subjects (48 per cohort) were random-
zed and vaccinated. In Cohorts I and II, no SAEs were reported. In
ohort III, no vaccine recipients experienced a SAE; 3/24 (12.5%)
lacebo recipients reported 4 SAEs. In Cohort III, the most com-
only reported non-serious AEs (NSAEs), were diarrhea [54.2%
13/24) in vaccine group, 33.3% (8/24) in placebo group], vomit-
ng [37.5% (9/24) in vaccine group, 50.0% (12/24) in placebo group],
nd pyrexia [37.5% (9/24) in vaccine group, 20.8% (5/24) in placebo
roup]. The NSAEs were mostly mild or moderate in intensity and
esolved or were resolving by the end of the study. In Cohort III,
he numbers of subjects with fecal vaccine-virus shedding (stool
ositive for rotavirus by EIA and conﬁrmed as vaccine-strain by
P6 PCR, which measures intact and degraded particles) were 3/23
13.0%) postdose 1, 2/21 (9.5%) postdose 2, and 3/22 (13.6%) post-
ose 3.
Conclusion: RotaTeqTM was generally well-tolerated in healthy
hinese adults, children and infants. The overall safety and fecal
accine-virus shedding observed in this study were generally com-
arable to results seen in larger studies conducted outside China.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.998fectious Diseases 16S (2012) e158–e316 e307
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Background: A 7-valent pneumococcal conjugate vaccine
(PCV7) was approved for use in Canada in June 2001, but was not
fully implemented in Ontario until 2005. To evaluate the impact of
PCV7 vaccination on prevalence, serotype and antimicrobial resis-
tance patterns of Streptococcus pneumoniae, we conductedactive
surveillancefor IPD cases in children of Ontario in Canada with 5
years old and under.
Methods: IPD has been a reportable disease in Ontario since
2001. Provincial datawereobtainedbycompiling laboratory results
fromthePublicHealthOntario Laboratories (PHOL) and theToronto
Invasive Bacterial Disease Network (TIBDN). Clinical isolates were
serotyped by Quellung reaction. Broth microdilution methods are
used for antimicrobial susceptibility testing according to 2011 CLSI
guidelines.
Results: In total 295 IPD cases (73, 63, 70, 35 and 54 respec-
tively from 2007 to 2011) were observed. Overall PCV7 serotypes
decreased gradually in the post-PCV7 era. However, the number of
cases caused by several non-PCV7 serotypes increased: 19A, 7F,
3 and 22F (Figure). Serotype 19A remained the most predomi-
nant type, with an increase from 30% to 42% during 2007-2009,
and 22% during 2010-2011. Serotype 7F increased to 20% in 2011.
29.4% of all clinical isolates were resistant to one or more antibi-
otics (n =146, 2007-9 isolates). Of all isolates, the rate ofmulti-drug
resistance and penicillin non-susceptibility were 25% and 11.6%
respectively. 2 penicillin susceptible isolates were shown to be
amoxicillin nonsusceptible (intermediate,MIC=4g/ml). This is of
clinical relevance, as the current CLSI guidelines advise that peni-
e l of Infectious Diseases 16S (2012) e158–e316
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Streptococcus pneumoniae serotype proﬁle (2007-2011)
Conclusion: Serotype 19A has become the most important
ause of IPD in children post-PCV7. Non-vaccine serotype 7F and
have also increased. Serotype 19A showed high penicillin non-
usceptibility (22%) and high occurrence of multi-drug resistance
39%) among the isolates.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.999
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aculovirus systemasaproteinexpressionof inﬂuenzaA/H1N1p
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Background: Inﬂuenza is a zoonotic disease that has caused
ajor epidemics in the world in both humans and animals caus-
ng economic losses. Inﬂuenza A/H1N1/2009 virus is circulating
mong human and animal populations. It is, therefore, important
o develop strategies to produce protective antibody responses
gainst H1N1 virus. There have been international efforts to obtain
nd a universal vaccine for different subtypes of the virus. Proteins
hat can be used to achieve this purpose are structural. So the aim
f this study was to obtain the M and NS1 recombinant proteins in
ddition to the HA1 of inﬂuenza virus strain A/H1N1/2009 (Paris
009) using baculovirus systems for used as vaccine and diagnostic
urposes
Methods: The genes M1, NS1, HA and NP inﬂuenza virus
/H1N1/Paris/2009 were ampliﬁed by RT-PCR and were subcloned
eparately into the vector pST-28 and subsequently cloned into
he pFastBac vector to obtain four recombinant baculovirus with
hich separately Sf9 insect cells were infected. Insect cells extracts
ere used to identify proteins by western blot using monoclonal
ntibodies and a pool of sera from people infected with the virus.
Results: In the western blot were recognized a protein of ∼26
Da (M protein), a ∼26 kDa (NS1 protein) and another of ∼65 kDa
HA1 protein). This monoclonal antibody using both patient sera
hereby demonstrated that these proteins retained their antigenic
roperties.Conclusion: We conclude that the baculovirus expression sys-
tem was efﬁcient for obtaining these four recombinant proteins of
inﬂuenzavirus. Theseproducts couldbeusedas immunogenand/or
reactive for ELISA test.
http://dx.doi.org/10.1016/j.ijid.2012.05.1000
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Background:After theﬁrst caseofpandemic InﬂuenzaA (H1N1)
in Laos in 2009, 978,390 high risk persons were vaccinated (preg-
nant women, chronically ill and health care workers). No ofﬁcial
and only 14 unofﬁcial reports of adverse events following immu-
nization (AEFI) were reported to the national passive surveillance
system. This triggeredan investigation into thequality andquantity
of adverse event reports in two provinces where patients received
pandemic vaccine with or without tetanus vaccine.
Methods: In November 2010, 1,204 persons from 73 randomly
selected villages in eight districts across Luangprabang and Savan-
nakhet provinces were interviewed about being at risk of inﬂuenza
complications andpost-vaccination symptoms.AEFIwasdeﬁnedas
any person receiving vaccine and any of the following symptoms
within threedays: report of fever, headache, nausea, local reactions,
myalgia, paralysis, shock, seizures or spontaneous abortion.
Results: Seventy-eight (6.5%) of 1,204 persons reported an AEFI
that met the case deﬁnition. No serious adverse events such as
seizure, shock, deathor abortionwere reported. 71% reportedmyal-
